Avogaro P, Bittolo Bon G, Cazzolato G, Soldan S, Bufalino L
Atherosclerosis Research Regional Centre, Venice, Italy.
Drugs Exp Clin Res. 1989;15(6-7):325-33.
The effects of the new fibric acid derivative beclobrate (100 mg) on some plasma lipidic and apoproteic parameters in 20 patients with type IIb hyperlipoproteinaemia were matched in a randomized cross-over study to a sustained release formulation of bezafibrate (400 mg). Inclusion criteria were: total cholesterol (TC) plasma levels greater than 260 mg/dl and triglyceride (TG) levels greater than 200 mg/dl, after a 2-month period of isocaloric diet. The drugs were administered once a day for 8 weeks, and then crossed-over after 8 weeks of wash-out for another 8 week period of treatment. Both drugs were significantly effective in reducing TC and TG, and in increasing HDL-C plasma levels, but only beclobrate significantly decreased Apo B and LDL-C whereas bezafibrate seemed to be more active in increasing HDL-C levels. The electrophoretic pattern of LP in patients treated with beclobrate revealed a decrease of VLDL, a normalization of the LDL fraction and an increase of HDL. The tolerability was generally good.
在一项随机交叉研究中，将新的纤维酸衍生物氯贝酸（100毫克）对20例IIb型高脂蛋白血症患者某些血浆脂质和载脂蛋白参数的影响，与苯扎贝特缓释制剂（400毫克）进行了匹配对照。纳入标准为：在为期2个月的等热量饮食后，血浆总胆固醇（TC）水平大于260毫克/分升，甘油三酯（TG）水平大于200毫克/分升。药物每日服用一次，持续8周，然后在8周的洗脱期后交叉，再进行8周的治疗期。两种药物在降低TC和TG以及提高血浆HDL-C水平方面均有显著效果，但只有氯贝酸能显著降低载脂蛋白B和LDL-C，而苯扎贝特在提高HDL-C水平方面似乎更有效。接受氯贝酸治疗的患者中脂蛋白的电泳图谱显示VLDL减少，LDL部分正常化，HDL增加。耐受性总体良好。
